title: The effect of granulocyte colony-stimulating factor administration in healthy donors before bone marrow harvesting.
abstract: To investigate whether granulocyte colony-stimulating factor (G-CSF) administration to donors before harvest may lighten the burden imposed on them and accelerate the bone marrow (BM) recovery, we administered 2 microgram/kg/d of G-CSF for five consecutive days before the marrow harvest. All of the donors tolerated the G-CSF administration well without severe adverse events. After 5 d of G-CSF treatment, CD34+ cells and granulocyte-macrophage colony-forming units (GM-CFU) in the donors' BM exceeded baseline values by 4.2-fold (range 0.71-316) and 1.6-fold (0.28-118) respectively. The concentration of total nucleated cells (x 107/ml) in the graft increased from 1.61 (0.95-3.23) to 2.44 (1.27-4.01). Although we collected 1020 ml of BM and obtained 1.50 x 1010 nucleated cells from unprimed donors, 940 ml of BM were sufficient to obtain 2.14 x 1010 nucleated cells from primed donors. However, G-CSF-primed BM did not shorten the time to tri-lineage engraftment and the duration of hospitalization compared with unprimed BM, although primed BM contained more CD34+ cells than baseline values. We consider that the advantages of BM priming are not the acceleration of BM recovery but rather the reduction of blood loss during BM harvesting.
authors.affiliation: Department of Haematology/Oncology, The Institute of Medical Science, University of Tokyo, Tokyo, Japan. utako-tky@umin.ac.jp
authors.forename: U
authors.initials: U
authors.lastname: MacHida
authors.forename: A
authors.initials: A
authors.lastname: Tojo
authors.forename: S
authors.initials: S
authors.lastname: Takahashi
authors.forename: T
authors.initials: T
authors.lastname: Iseki
authors.forename: J
authors.initials: J
authors.lastname: Ooi
authors.forename: H
authors.initials: H
authors.lastname: Nagayama
authors.forename: N
authors.initials: N
authors.lastname: Shirafuji
authors.forename: S
authors.initials: S
authors.lastname: Mori
authors.forename: Y
authors.initials: Y
authors.lastname: Wada
authors.forename: K
authors.initials: K
authors.lastname: Ogami
authors.forename: Y
authors.initials: Y
authors.lastname: Yamada
authors.forename: H
authors.initials: H
authors.lastname: Sakamaki
authors.forename: T
authors.initials: T
authors.lastname: Maekawa
authors.forename: K
authors.initials: K
authors.lastname: Tani
authors.forename: S
authors.initials: S
authors.lastname: Asano
mesh_terms: D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis; D016063:Blood Loss, Surgical / Q000517:prevention & control; D001854:Bone Marrow Cells / Q000166:cytology* / Q000187:drug effects; D016026:Bone Marrow Transplantation; D002452:Cell Count; D002455:Cell Division / Q000187:drug effects; D005260:Female; D006086:Graft vs Host Disease / Q000473:pathology; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D013268:Stimulation, Chemical; D014019:Tissue Donors; D020858:Tissue and Organ Harvesting / Q000379:methods
chemical_list: D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor